Incidence, Associated Factors, and Prognosis of Liver Dysfunction in Children with Community-Acquired Pneumonia: A Multicenter Prospective Study

Abstract

Objective Community-acquired pneumonia with abnormal liver function is not uncommon. There is no systematic study on the clinical characteristics of liver dysfunction in children with community-acquired pneumonia. We aimed to evaluate the characteristics and prognosis of liver dysfunction in children with community-acquired pneumonia.

Methods This study was a multicenter prospective study involving 26 hospitals in Sichuan Province from June 2020 to June 2021. The characteristics of liver dysfunction in children with community-acquired pneumonia were recorded and analyzed according to different factors such as age, medical condition, level of transaminase in liver function, and time for liver function recovery.

Results A total of 4,623 hospitalized children with pneumonia were included. Among them, 592 children had liver dysfunction, accounting for the 12.8% (592/4,623). The degree of liver function injury was more obvious in infants and in children of severe pneumonia group (average ranks were 288.95 and 319.34). The liver lesion was more serious in the group of children less than 1 year old (p = 0.000). The median time to recovery of liver function was 8 days (interquartile range: 6–15.5 days), whereas the fastest recovery was 3 days, and the longest recovery period was 162 days.

Conclusion Community-acquired pneumonia with abnormal liver function is very common. Young age and severe pneumonia are risk factors for liver dysfunction. The recovery time of liver enzymes is not short. Infants and children with severe pneumonia need closer follow-up.

Keywords

children - community-acquired pneumonia - liver dysfunction

Publikationsverlauf

Eingereicht: 04. März 2024

Angenommen: 25. Juli 2024

Artikel online veröffentlicht:
05. September 2024

• References

• 1 Lee Y, Yi DY, Lee YM, Choi SY, Choi YJ, Lee KJ. A multicenter study of real-world practice for management of abnormal liver function tests in children with acute infectious diseases. J Korean Med Sci 2021; 36 (47) e310
• 2 Yazigi N, Balistreri WF. Viral hepatitis. In: Kliegman RM, Stanton BF, , St. Geme JW lll, Schor NF, Behrman RE. eds. Nelson Textbook of Pediatrics. 19th ed.. Philadelphia: Elsevier Saunders; 2011: 1393-1394
• 3 Jang M, Oh MS, Oh SC, Kang KS. Distribution of diseases causing liver function test abnormality in children and natural recovery time of the abnormal liver function. J Korean Med Sci 2016; 31 (11) 1784-1789
• 4 Scott JA, Brooks WA, Peiris JS, Holtzman D, Mulholland EK. Pneumonia research to reduce childhood mortality in the developing world. J Clin Invest 2008; 118 (04) 1291-1300
• 5 Juvén T, Mertsola J, Waris M. et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000; 19 (04) 293-298
• 6 Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet 2005; 365 (9465) 1147-1152
• 7 Izadnegahdar R, Cohen AL, Klugman KP, Qazi SA. Childhood pneumonia in developing countries. Lancet Respir Med 2013; 1 (07) 574-584
• 8 Chee E, Huang K, Haggie S, Britton PN. Systematic review of clinical practice guidelines on the management of community acquired pneumonia in children. Paediatr Respir Rev 2022; 42: 59-68
• 9 Helms CM, Viner JP, Sturm RH, Renner ED, Johnson W. Comparative features of pneumococcal, mycoplasmal, and legionnaires' disease pneumonias. Ann Intern Med 1979; 90 (04) 543-547
• 10 Kountouras D, Deutsch M, Emmanuel T, Georgiadis G, Koskinas J. Fulminant Mycoplasma pneumoniae infection with multi-organ involvement: a case report. Eur J Intern Med 2003; 14 (05) 329-331
• 11 Jujaray D, Juan LZ, Shrestha S, Ballgobin A. Pattern and significance of asymptomatic elevation of liver enzymes in mycoplasma pneumonia in children. Clin Pediatr (Phila) 2018; 57 (01) 57-61
• 12 Lan G, Yehong W. Clinical analysis of liver function abnormality in children. J Pediatr Pharmacy 2012; 18 (11) 7-9
• 13 Dai D, Feiqiu W, Huabo C, Shaoming Z. Clinical analysis of severe liver damage in children. J Clin Pediatr 2015; 33 (10) 846
• 14 Kountouras D, Deutsch M, Emmanuel T, Georgiadis G, Koskinas J. Fulminant Mycoplasma pneumoniae infection with multi-organ involvement: a case report. Eur J Intern Med 2003; 14 (05) 329-331
• 15 Song J. Retrospective study of 216 cases of infant with liver dysfunction. Jianyan Yixue Yu Linchuang 2009; 7 (08) 703-705
• 16 Elin RJ, Wolff SM. Biology of endotoxin. Annu Rev Med 1976; 27 (27) 127-141
• 17 Huang X, Zhu X, Cheng SH. Clinical features, diagnosis and treatment of 216 community acquired pneumonia patients complicated with liver injury. Pract J Cardiac Cereb Pneuma Vasc Dis. 2015; (08) 98-100
• 18 Meyer Sauteur PM, van Rossum AMC, Vink C. Mycoplasma pneumoniae in children: carriage, pathogenesis, and antibiotic resistance. Curr Opin Infect Dis 2014; 27 (03) 220-227
• 19 Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev 2017; 30 (03) 747-809
• 20 Daxboeck F, Khanakah G, Bauer C, Stadler M, Hofmann H, Stanek G. Detection of Mycoplasma pneumoniae in serum specimens from patients with mycoplasma pneumonia by PCR. Int J Med Microbiol 2005; 295 (04) 279-285
• 21 Dudnyk V, Pasik V. Liver dysfunction in children with community-acquired pneumonia: the role of infectious and inflammatory markers. J Educ Health Sport 2021; 11 (11) 169-181
• 22 Shen T, Liu Y, Shang J. et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology 2019; 156 (08) 2230-2241.e11
• 23 Fan C, Li Z. Clinical research of azithromycin in treatment of mycoplasma pneumonia on liver function of the related factors and prognosis. Gu Chi Med 2012; 10 (23) 448-450